| Literature DB >> 26222677 |
Sujit Kootala1, Masahiro Tokunaga2, Jöns Hilborn3, Yasuhiko Iwasaki4.
Abstract
Osteoporosis involves hyperactive osteoclasts. A large number of current drugs result in side effects affecting their efficacy in the clinic. Polyphosphoesters are unique polymeric biomaterials because of their biocompatibility, biodegradability, and bone affinity. We studied the viability and ability of human osteoclasts to resorb bone when dosed with poly(ethylene sodium phosphate) (PEP·Na). This did not trigger any change in osteoblast cell viability, however the polymer diminished human osteoclasts and their ability to resorb bone at concentrations as low as 10(-4) m · mL(-1). This is the first report to validate the possibility of using polyphosphoesters for selective inhibition of human osteoclast functions, indicating its potential to be used as an effective polymer prodrug for treatment of osteoporosis.Entities:
Keywords: biocompatibility; bone therapy; osteoblast; osteoclast; polyphosphoesters
Mesh:
Substances:
Year: 2015 PMID: 26222677 DOI: 10.1002/mabi.201500166
Source DB: PubMed Journal: Macromol Biosci ISSN: 1616-5187 Impact factor: 4.979